|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 7,687,075 (Colonic Purgative Tablets with Sodium Phosphate and Polyethylene Glycol 7,000–9,000)
U.S. Patent 7,687,075 claims a fixed-dose colonic purgative tablet built around a sodium phosphate + polyethylene glycol (PEG 7,000–9,000 Da, typically PEG 8000) binder system that is uniformly distributed to maintain tablet integrity, plus optional lubricant and specific dosing schedules for pre-colonoscopy bowel cleansing. The claim set is heavily composition-and-structure anchored (weight ranges, PEG molecular weight band, “distributed/binds” language, tablet disintegration timing) and then expands into dose regimens and kit packaging, plus a manufacturing method (heat to PEG melt then compress).
What does U.S. 7,687,075 claim cover: sodium phosphate + PEG binder tablets for colonoscopy cleansing?
Core claim theme: a tablet that uses PEG (7,000–9,000 Da) as a binder/matrix that associates with sodium phosphate to keep the tablet intact through processing and dosing, enabling a high total sodium phosphate dose (e.g., 42–60 grams per dosage regimen) administered orally before colonoscopy.
What are the “essential elements” across independent claim 1 and its dependent fallbacks?
- Dosage form: solid dosage tablet, oral administration, colonic purgative.
- Actives: sodium phosphate and PEG 7,000–9,000 Da.
- PEG amount: 7.5% to 15% by weight (in claim 1).
- PEG molecular weight band: 7,000 to 9,000 daltons.
- Distribution/functional structural limitation: PEG is uniformly distributed in the tablet so that PEG binds sodium phosphate “to maintain the tablet form.”
- Total dose: 42–60 grams of sodium phosphate per dosage.
- Optional tablet excipient: lubricant (claims 3–4, 19, 26, 29).
This means the patent’s infringement and non-infringement fault lines are likely to cluster around:
- whether the formulation uses PEG in the 7,000–9,000 Da band (not a different PEG),
- whether PEG is present at 7.5–15% w/w (or the dependent ranges), and
- whether PEG performs the binder role through distribution/association with sodium phosphate rather than being absent or replaced by another binder system.
How broadly is sodium phosphate defined?
Dependent claim 2 limits “sodium phosphate” to:
- monobasic sodium phosphate, dibasic sodium phosphate, or combinations.
Other dependent claims provide specific composition splits:
- Claim 5: monobasic 45–75% and dibasic 15–30%, with PEG 8,000 5–20% and magnesium stearate 0.10–1.50%.
- Claim 6: sodium phosphate 15–90% with PEG 5–20% and magnesium stearate 0.10–1.50%.
- Claims 17–18, 28, 38: specific tablet masses (monobasic ~1100 mg, dibasic ~398 mg).
What formulation guardrails are added via “matrix” language?
Two distinct but related functional structural formulations appear:
- Claim 1: uniform distribution such that PEG binds sodium phosphate to maintain tablet form.
- Claim 5 and claim 6: PEG provides a matrix where sodium phosphate associates to maintain the tablet form.
Dependent claim 48 tightens binder identity: “tablet binder consists essentially of polyethylene glycol.” That is a high-leverage narrowing clause that can matter in disputes where other binders are added.
Which parts of the claims are most likely to be enforceable: composition ranges, PEG MW limits, and tablet integrity language?
Most enforceable claim “hooks” (high litigation leverage because they are objective and formulation-specific):
- PEG molecular weight band (7,000–9,000 Da).
- PEG weight fraction (7.5–15% in claim 1; 5–20% in later ranges).
- Functional association requirement tied to physical performance: “PEG uniformly distributed … binds sodium phosphate together to maintain the tablet form.”
- Total sodium phosphate dosage (42–60 g per dosing).
- Manufacturing method in claim 31: heat mixture to PEG melting point, then compress (this can be both a patentability support and an infringement path if a manufacturer follows that method).
- Disintegration within about 11 minutes (claims 10, 35–38). This is a performance parameter that can become a key evidentiary focal point.
Most likely to narrow infringement (dependent claim dependencies that reduce scope):
- Specific PEG molecular weight exact value: claim 8 (PEG 8,000), claim 22 and 23.
- Specific PEG weight: claim 9 (10% w/w).
- Specific per-tablet masses and magnesium stearate mass: claims 17–21.
- Specific tablet counts and dosing schedules: claims 11–15, 39–47.
What do the dependent claims add: lubricant, disintegration timing, tablet mass, and dosing regimen?
Lubricant / magnesium stearate
- Claim 3 adds “lubricant.”
- Claim 4 specifies magnesium stearate.
- Multiple later dependent claims (19, 20, 26, 29) fix magnesium stearate presence or level.
- Claim 5 includes magnesium stearate 0.10–1.50%.
Tablet disintegration timing
- Claim 10: tablet disintegrates within about 11 minutes.
- Claims 35–38 repeat this limitation across other dependent branches (claims 1, 6, 16, 24).
This is likely intended to distinguish from faster disintegrating tablets or different binder systems.
Tablet and dosage unit quantification
Claims 11–13 map the total sodium phosphate dose to tablet counts and timing.
- Claim 11: 48 g sodium phosphate divided between 32 tablets.
- Claim 12: 20 tablets total, taken as 4 tablets at a time with 8 oz clear liquid every 15 minutes the evening before colonoscopy.
- Claim 13: 12 tablets total, taken as 4 tablets at a time with 8 oz clear liquid beginning 3–5 hours before colonoscopy.
These regimen-dependent claims are not needed for the general “formulation” coverage but can become decisive for product-specific challenges.
Specific per-tablet formulation
- Claim 16 consolidates: PEG 7.5–15% and about 1.5 g sodium phosphate per tablet, PEG as binder MW 7,000–9,000.
- Claims 17–21 fix:
- monobasic ~1100 mg,
- dibasic ~398 mg,
- magnesium stearate inclusion and level (~8.4 mg),
- tablet mass ~1676 mg.
Total product dosing variations
- Claim 27: 48 g sodium phosphate in tablet form; each tablet contains about 1.5 g sodium phosphate; tablets include PEG 7.5–15% PEG 8000 with distribution binding.
- Claim 30: four tablets taken every 15 minutes (regimen structure).
- Claims 39–44 and 43–44 specify tablet counts (32 and 40 in some branches; also 32 and 40 across dependent paths).
- Claims 46–47 provide regimen timing totals:
- evening: four tablets every 15 minutes, total 20 tablets,
- day-of: four tablets every 15 minutes, total 12 tablets.
Which manufacturing method is claimed: heating PEG/sodium phosphate to PEG melt and compressing?
Claim 31 introduces a process limitation attached to a tablet formulation:
- Heat mixture of sodium phosphate and PEG to the melting point of PEG.
- Compress into tablets.
- Dependent claims add cooling:
- claim 33: allow to cool before compression.
- claim 34: allow to cool down overnight before compression.
From a patent landscape standpoint, this process claim can matter in two ways:
- It can provide additional patentability distance from prior tablets made by direct blending without melt heating.
- It can create a method infringement route if a competitor uses the same melt-and-compress approach.
How does the claim scope map to likely product design choices and generic/OTC competitive risk?
PEG molecular weight substitution risk
If an applicant uses:
- PEG with MW outside 7,000–9,000, the formulation may exit the claimed MW range.
- PEG 4000 or PEG 3350 would likely avoid literal MW coverage.
- PEG 10,000+ is also outside the claimed band (unless it still falls inside asserted interpretive parameters, but the claim text is numeric).
Binder role substitution risk
If magnesium stearate is not the issue, binder identity is.
- Dependent claim 48 “binder consists essentially of polyethylene glycol” increases avoidance paths that use co-binders (e.g., povidone, HPMC, starches) unless PEG remains the “consists essentially” binder anchor under the legal standard.
PEG level substitution risk
Claim 1 uses 7.5–15%; other claims use 5–20%.
A design that uses PEG outside those ranges can reduce literal exposure.
Tablet integrity performance and disintegration
Even if formulation composition hits ranges, disintegration within about 11 minutes is another fault line.
A competitor could target slower or faster disintegration (while still meeting bowel cleansing performance) to avoid that specific dependent performance limitation, though composition claims without the disintegration parameter remain.
Dose regimen / timing
Regimen claims (claims 11–15, 12–13, 30, 46–47) create another route to narrow infringement:
- A competitor using different scheduling or tablet counts could avoid those dependent regimen limitations.
- But if they still make tablets that meet the independent composition claim elements, regimen changes may not fully eliminate risk.
What is the practical patent landscape: how U.S. 7,687,075 likely clusters with surrounding sodium phosphate bowel-prep IP?
Given the claim structure, U.S. 7,687,075 most plausibly sits in a dense family space around:
- sodium phosphate oral bowel preparations in tablet format,
- PEG binder systems with defined MW bands,
- tablet integrity/disintegration targets, and
- regimen and kit packaging.
Even without listing the full family and citing every related patent, the claim content itself indicates the patent is not only about the actives (sodium phosphate) but about the binder chemistry and tablet manufacturing workflow. That typically places it downstream of earlier compositions and upstream of later product improvements in the same dosage form.
What are the key “freedom-to-operate” positioning points inside the claims?
- Literal formulation coverage is narrowest on PEG MW 7,000–9,000 and PEG w/w fraction.
- Functional “binds/maintain tablet form” language is central and can require evidence about how PEG is distributed and how it interacts with sodium phosphate in the tablet matrix.
- Dependent binder-exclusive clause (claim 48) provides a high-value avoidance or attack point for co-binder formulations.
- Disintegration within about 11 minutes is another measurable dependent hook.
- Method claim 31 is a third axis of infringement risk tied to melting PEG before compression.
Timeline and exclusivity: what does the claim structure imply about remaining enforceability?
No filing, grant, or expiration dates were provided in the prompt, and without the underlying bibliographic record for U.S. 7,687,075, no accurate exclusivity or expiration timeline can be derived here.
Key Takeaways
- U.S. 7,687,075 is anchored on colonic purgative sodium phosphate tablets where PEG (7,000–9,000 Da, typically PEG 8000) is uniformly distributed to bind sodium phosphate and maintain tablet form.
- The patent’s claim scope is strongest on composition constraints (PEG MW band and weight %, sodium phosphate inclusion and total dosing grams) and reinforced by process (heat-to-PEG-melt then compress) and performance (disintegrate in ~11 minutes).
- Dependent claims add magnesium stearate lubrication, exact per-tablet masses, tablet counts, and specific dosing regimens around colonoscopy timing.
- The most direct design-around levers are PEG molecular weight outside 7,000–9,000, PEG loading outside the claimed ranges, changing binder system away from PEG-only “consists essentially”, and altering disintegration timing and dosing schedule to avoid dependent performance/regimen limitations.
FAQs
-
Does U.S. 7,687,075 require PEG to be PEG 8000 specifically?
No. Claim 1 requires PEG with average molecular weight 7,000–9,000 Da; PEG 8000 is expressly covered in dependent claims.
-
Can a formulation that uses sodium phosphate but a different binder avoid the patent?
Potentially. The claims require PEG as the binder/matrix with specific MW and functional distribution binding language, and claim 48 narrows to binder “consists essentially of polyethylene glycol.”
-
Is magnesium stearate required to infringe?
Not for claim 1. Magnesium stearate is introduced in dependent claims; claim 1 only requires sodium phosphate and PEG meeting the MW and distribution/weight constraints.
-
What is the significance of the “tablet disintegrates within about 11 minutes” limitation?
It appears only in dependent claim branches (claims 10 and related dependent repetitions). Avoiding that specific performance target can help on those dependent paths, though independent composition claims may still apply.
-
Does the manufacturing method claim change the product-level risk for competitors?
It adds a separate infringement axis: if a competitor uses a process that heats PEG/sodium phosphate mixture to PEG’s melting point and then compresses (with cooling steps as claimed), method exposure can be implicated even if the competitor adjusts formulation details.
References
No external sources were provided in the prompt, and no bibliographic or prosecution history for U.S. 7,687,075 (publication number, filing date, assignee, full specification, or related family patents) was included.
More… ↓
⤷ Start Trial
|
